Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Income towards Parent Company: 2010-2025

Historic Income towards Parent Company for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Income towards Parent Company rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • Per Heron Therapeutics' latest filing, its Income towards Parent Company stood at -$4.1 million for Q3 2025, which was down 150.03% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Income towards Parent Company registered a high of $4.2 million during Q4 2024, and its lowest value of -$62.9 million during Q1 2022.
  • Its 3-year average for Income towards Parent Company is -$11.3 million, with a median of -$4.8 million in 2024.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first dropped by 20.74% in 2022, then soared by 165.74% in 2025.
  • Over the past 5 years, Heron Therapeutics' Income towards Parent Company (Quarterly) stood at -$53.5 million in 2021, then spiked by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then spiked by 140.83% to $4.2 million in 2024, then grew by 8.19% to -$4.1 million in 2025.
  • Its Income towards Parent Company was -$4.1 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.2 million in Q1 2025.